Small-molecule Bax agonists for cancer therapy

Area of Science:

• Molecular Biology
• Biochemistry
• Oncology

Background:

• Bax is a key regulator of apoptosis, a programmed cell death process.
• Serine 184 (S184) on Bax acts as a critical switch for its pro-apoptotic function.

Purpose of the Study:

• To identify small molecules that modulate Bax activity by targeting the S184 site.
• To investigate the therapeutic potential of Bax agonists in cancer treatment.

Main Methods:

• Utilized UCSF-DOCK software to screen the NCI small molecule library against the S184 pocket of Bax.
• Assessed the effects of identified compounds (SMBA1-3) on Bax conformation, oligomerization, and apoptosis induction in human lung cancer cells.
• Evaluated the in vivo efficacy and toxicity of SMBA1 in a lung tumor model.

Main Results:

• Discovered three small-molecule Bax agonists (SMBA1-3) that bind to the S184 pocket.
• These agonists induce Bax conformational changes, inhibit S184 phosphorylation, promote Bax insertion into mitochondrial membranes, and trigger Bax oligomerization.
• SMBA1 demonstrated potent suppression of lung tumor growth in vivo through Bax-dependent apoptosis, with no significant normal tissue toxicity.

Conclusions:

• Small-molecule Bax agonists represent a novel class of anticancer agents.
• Selective activation of Bax offers a promising therapeutic strategy for lung cancer and other Bax-expressing malignancies.